NEW YORK (GenomeWeb News) – Platypus Technologies has received a $396,000 grant from the National Cancer Institute to develop a high-throughput screening system for cancer therapeutics.
The two-year grant will fund the further development of Platypus' Oris assay format into a 384-well cell migration assay suitable for high-throughput screening of chemical libraries for cancer therapeutics.
"This intended product has the potential to streamline the drug discovery process by facilitating rapid screening of molecular libraries for development of therapeutics that block cancer cell metastasis and lead to novel cancer drugs," Platypus Technologies President and CEO Richard Schifreen said in a statement.